Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
- Published in:
- Liver International, 2018, v. 38, n. 9, p. 1571, doi. 10.1111/liv.13708
- By:
- Publication type:
- Article
Works matching AU YOUNES, ZIAD
Results: 13
1
2
Functional MRI for the Assessment of Gastric Motility--A Better Test?
- Published in:
- 1999
- By:
- Publication type:
- Abstract
3
Role of growth factors in oesophageal mucosal healing: A work in progress.
- Published in:
- Journal of Gastroenterology & Hepatology, 1998, v. 13, p. S156, doi. 10.1111/j.1440-1746.1998.tb01869.x
- By:
- Publication type:
- Article
4
Role of growth factors in oesophageal mucosal healing: A work in progress.
- Published in:
- Journal of Gastroenterology & Hepatology, 1998, v. 13, n. 11S4, p. S156
- By:
- Publication type:
- Article
5
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 4, p. 628, doi. 10.1093/cid/ciz243
- By:
- Publication type:
- Article
6
Congenital Esophageal Stenosis: Clinical and Endoscopic Features in Adults.
- Published in:
- Digestive Diseases, 1999, v. 17, n. 3, p. 172, doi. 10.1159/000016922
- By:
- Publication type:
- Article
7
Antimicrobial Treatment of Intra-Abdominal Infections.
- Published in:
- Digestive Diseases, 1998, v. 16, n. 1, p. 47, doi. 10.1159/000016848
- By:
- Publication type:
- Article
8
Molecular and Genetic Advances in Gastrointestinal Cancer: State of the Art.
- Published in:
- Digestive Diseases, 1997, v. 15, n. 4/5, p. 275, doi. 10.1159/000171604
- By:
- Publication type:
- Article
9
Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1...
- Published in:
- Clinical Infectious Diseases, 2015, v. 60, n. 4, p. 608, doi. 10.1093/cid/ciu865
- By:
- Publication type:
- Article
10
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 9, p. 1021, doi. 10.1093/ecco-jcc/jjy049
- By:
- Publication type:
- Article
11
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease.
- Published in:
- Journal of Crohn's & Colitis, 2018, v. 12, n. 9, p. 1014, doi. 10.1093/ecco-jcc/jjy070
- By:
- Publication type:
- Article
12
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy.
- Published in:
- Journal of Medical Virology, 2019, v. 91, n. 7, p. 1307, doi. 10.1002/jmv.25448
- By:
- Publication type:
- Article
13
752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-752-P
- By:
- Publication type:
- Article